Altered Stoichiometry of FKBP12.6 Versus Ryanodine Receptor as a Cause of Abnormal Ca\textsuperscript{2+} Leak Through Ryanodine Receptor in Heart Failure

Masafumi Yano, MD, PhD; Kaoru Ono, MD; Tomoko Ohkusa, MD, PhD; Masae Suetsugu, BS; Masateru Kohno, MD; Takayuki Hisaoka, MD; Shigeki Kobayashi, MD, PhD; Yuji Hisamatsu, MD, PhD; Takeshi Yamamoto, MD, PhD; Michihiro Kohno, MD, PhD; Naoya Noguchi, MD, PhD; Shin Takasawa, MD, PhD; Hiroshi Okamoto, MD, PhD; Masunori Matsuzaki, MD, PhD

Background—In the pathogenesis of cardiac dysfunction in heart failure, a decrease in the activity of the sarcoplasmic reticulum (SR) Ca\textsuperscript{2+}-ATPase is believed to be a major determinant. Here, we report a novel mechanism of cardiac dysfunction revealed by assessing the functional interaction of FK506–binding protein (FKBP12.6) with the cardiac ryanodine receptor (RyR) in a canine model of pacing-induced heart failure.

Methods and Results—SR vesicles were isolated from left ventricular muscles (normal and heart failure). The stoichiometry of FKBP12.6 per RyR was significantly decreased in failing SR, as assessed by the ratio of the B\textsubscript{max} values for [\textsuperscript{3}H]dihydro-FK506 to those for [\textsuperscript{3}H]ryanodine binding. In normal SR, the molar ratio was 3.6 (1 FKBP12.6 for each RyR monomer), whereas it was 1.6 in failing SR. In normal SR, FK506 caused a dose-dependent Ca\textsuperscript{2+} leak that showed a close parallelism with the conformational change in RyR. In failing SR, a prominent Ca\textsuperscript{2+} leak was observed even in the absence of FK506, and FK506 produced little or no further increase in Ca\textsuperscript{2+} leak and only a slight conformational change in RyR. The level of protein expression of FKBP12.6 was indeed found to be significantly decreased in failing SR.

Conclusions—An abnormal Ca\textsuperscript{2+} leak through the RyR is present in heart failure, and this leak is presumably caused by a partial loss of RyR-bound FKBP12.6 and the resultant conformational change in RyR. This abnormal Ca\textsuperscript{2+} leak might possibly cause Ca\textsuperscript{2+} overload and consequent diastolic dysfunction, as well as systolic dysfunction. (Circulation. 2000;102:2131-2136.)

Key Words: sarcoplasmic reticulum ■ heart failure ■ calcium ■ ion channels
altered in heart failure. When we found that the addition of FK506 to normal SR vesicles decreased the rate of drug-induced Ca\(^{2+}\) release toward that seen in failing SR vesicles (unpublished data), we hypothesized that the mode of interaction between FKBP12.6 and the RyR-2 may be altered in heart failure and that this might be the major cause of the impaired channel gating function. The goal of this study was to investigate this hypothesis.

Methods

Materials
Fluo 3 was obtained from Molecular Probes, and sulfosuccinimidyl 3-(2-(7-azido-4-methylcoumarin-3-acetoxyethyl)dithio)propionate (SAED) was from Pierce. FK506 was provided by Fujisawa Pharmaceutical Co, Ltd. \(^{[3}H\)ryanodine and \(^{[3}H\)dihydro-FK506 were purchased from Du Pont NEN. A monoclonal antibody against the canine cardiac ryanodine receptor was from Affinity Bioreagents, Inc. Rat recombinant FKBP12.6 and rabbit anti-FKBP12.6 antiserum directed against the sequence KKFDSSRDRNKPFK were used for immunoblot analysis.

Production of Pacing-Induced Heart Failure
In 12 beagle dogs of either sex weighing 10 to 14 kg, heart failure was induced by 21 day of rapid ventricular pacing at a rate of 250 bpm with an externally programmable miniature pacemaker (Medtronic Inc), as described previously.\(^{12,14}\) Approximately 1 hour after termination of rapid ventricular pacing, left ventricular (LV) pressure was measured under anesthesia by way of a 7F micromanometer (Millar) inserted percutaneously via the carotid artery, and 2D short-axis echocardiograms were obtained at the level of the papillary muscle.

The care of the animals and the protocols used were in accord with guidelines laid down by the Animal Ethics Committee of Yamaguchi University School of Medicine.

Preparation of SR Vesicles
SR vesicles were prepared as described previously,\(^{12,14}\) according to the method of Kranias et al.\(^{15}\)

\(^{[3}H\)Dihydro-FK506 and \(^{[3}H\)Ryanodine Binding Assays
\(^{[3}H\)Dihydro-FK506 binding was performed in CHAPS-solubilized SR by the LH-20 column method\(^{8,16,17}\) with some modifications. The SR vesicles (0.1 mg/mL) were first solubilized in FK506-binding buffer (20 mMol/L NaPO\(_4\), 1 mMol/L DTT, 0.25% CHAPS, and 0.01% NaN\(_3\)). Then, the solubilized vesicles were incubated for 30 minutes at 37°C in a binding mixture containing 1.25 to 20 nmol/L \(^{[3}H\)dihydro-FK506 (55 000 cpm/mmol). After this incubation, the samples were applied to a 3-mL Sephadex LH-20 column equilibrated in LH-20 column buffer (10 mMol/L NaPO\(_4\), 1 mMol/L DTT, 0.25% CHAPS, and 0.01% NaN\(_3\)) to separate free from bound ligand. Nonspecific binding was determined by the addition of 30 mMol/L unlabeled FK506.

The density of high-affinity \(^{[3}H\)ryanodine binding sites in SR vesicles was determined by Scatchard analysis of \(^{[3}H\)ryanodine binding isotherms, as described previously.\(^{12,14}\) The stoichiometry of FKBP per RyR was calculated directly from the ratio of the maximal number of binding sites (B\(_{\text{max}}\)) values for \(^{[3}H\)dihydro-FK506 binding and \(^{[3}H\)ryanodine binding.\(^{8,17}\)

\(\text{Ca}^{2+}\) Uptake and Leak Assays
SR vesicles (0.2 mg/mL) were incubated in 0.5 mL of solution containing 0.15 mol/L potassium gluconate, 1 mMol/L MgCl\(_2\), 0.2 mMol/L EGTA-calcium buffer (free [Ca\(^{2+}\)] of 0.3 mMol/L), 10 mMol/L Na\(_2\)PO\(_4\), and 20 mMol/L MOPS, pH 6.8. \(\text{Ca}^{2+}\) uptake was initiated by the addition of 0.5 mMol/L ATP into the cuvette, and the time course of \(\text{Ca}^{2+}\) uptake was monitored spectrofluorometrically with fluo 3 as a \(\text{Ca}^{2+}\) indicator (excitation at 480 nm, emission at 530 nm). After the \(\text{Ca}^{2+}\) uptake had reached a plateau, various concentrations of FK506 were added in the presence of 1 mMol/L thapsigargin to inhibit SR \(\text{Ca}^{2+}\)-ATP activity, and the resultant \(\text{Ca}^{2+}\) leak was monitored.

Site-Directed Labeling of RyR With a Fluorescent Conformational Probe
Specific fluorescence labeling of the RyR in SR vesicles was performed with the cleavable heterobifunctional cross-linking reagent SAED with the aid of polylysine as a site-specific carrier, as described previously.\(^{16-20}\) The specific methyl-coumarin-acetamido (MCA) labeling of the RyR in cardiac SR vesicles was confirmed by a fluorometric scan (excitation at 360 nm, emission at 440 nm) with a fluorescence spectrophotometer (F-2000; Hitachi) after electrophoresis had been carried out on 4% SDS-polyacrylamide gel.

Fluorescence Assays of the Protein Conformational Change
The time course of the FK506-induced changes in the fluorescence intensity of the RyR-bound MCA probe (excitation at 360 nm, emission at 440 nm) was monitored under the same conditions as those used for the \(\text{Ca}^{2+}\) leak assay (except that there was no fluo 3 in the reaction solution) with a fluorescence spectrophotometer (F-2000; Hitachi).

Immunoblot Analysis
Immunoblot analysis for FKBP12.6 was performed as previously described.\(^{13}\) Cardiac SR vesicles were electrophoresed on 15% gel for FKBP12.6 with Laemmli’s buffer system. The amount of protein recognized by anti-FKBP12.6 antiserum was measured by quantitative densitometry of immunoblots with NIH Image (National Institutes of Health) image-analysis software. Recombinant FKBP12.6 was loaded in the range 10 to 50 ng. Within this range, a linear increase in the density of FKBP12.6 was obtained by quantitative densitometry. The relative activity associated with FKBP12.6 in each sample (100 µg) was calculated by dividing its activity by that of the positive control (20 ng of recombinant FKBP12.6).

Statistics
Differences between 2 groups were analyzed with an unpaired t test. Statistical significance was taken at a value of \(P<0.05\).

<table>
<thead>
<tr>
<th>TABLE 1. Hemodynamic Data</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR, bpm</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Normal (n=6)</td>
</tr>
<tr>
<td>Heart failure (n=6)</td>
</tr>
</tbody>
</table>

HR indicates heart rate; LVPSP, LV peak systolic pressure; LVEDP, LV end-diastolic pressure; (+)dP/dt, peak positive dP/dt of LV pressure; t, time constant of LV pressure decay during isovolumic relaxation period; LVDd, LV end-diastolic diameter; LVDs, LV end-systolic diameter; and FS, fractional shortening. ([LVDd-LVDs]/LVDd×100). Data represent mean±SD.

*\(P<0.05\) vs control.
SR vesicles have a molar ratio of FKBP per Ca$^{2+}$ that is 3.6 in normal vesicles, indicating that approximately 2 to 3 mol FKBP have been lost from each tetramer of the Ca$^{2+}$ release channel.

Results

Characteristics of Animal Models

There were no significant differences between normal and heart failure groups in body weight (kg; normal 11.±1, heart failure 11.±3), LV weight (g; normal 56.7, heart failure 65.11), or protein yield with respect to SR vesicles (mg protein/g; normal 1.4±0.4, heart failure 1.2±0.2).

Hemodynamic data are summarized in Table 1. In the heart failure group, LV end-diastolic pressure was significantly increased. These data indicate that both systolic and diastolic functions were impaired in the heart failure group.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Normal (n=6)</th>
<th>Heart failure (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (kg)</td>
<td>11.±1</td>
<td>11.±3</td>
</tr>
<tr>
<td>LV weight (g)</td>
<td>56.7±7</td>
<td>65.11±11</td>
</tr>
<tr>
<td>Protein yield (mg protein/g)</td>
<td>1.4±0.4</td>
<td>1.2±0.2</td>
</tr>
</tbody>
</table>

Effects of FK506 on Ca$^{2+}$ Leak and Conformational Change of RyR

Figure 2A shows the concentration-dependence of the FK506 (0 to 100 µmol/L)–induced Ca$^{2+}$ leak in the 2 types of SR vesicles. After the addition of FK506, a Ca$^{2+}$ leak was observed in both groups, and the amount of Ca$^{2+}$ leak was increased. These data indicate that both sys
tolic and diastolic functions were impaired in the heart failure group.

![Figure 1](http://circ.ahajournals.org/)

**Figure 1.** [3H]dihydro-FK506 binding to SR vesicles isolated from normal (○) and failing (●) canine hearts. [3H]dihydro-FK506 binding to SR vesicles was measured as described under Methods. Each datum point is average of duplicate determinations. Inset: Scatchard plot of binding data.

<table>
<thead>
<tr>
<th>[3H]Ryanodine Binding</th>
<th>[3H]Dihydro-FK506 Binding</th>
</tr>
</thead>
<tbody>
<tr>
<td>$B_{max}$ (pmol/mg)</td>
<td>$K_d$ (nmol/L)</td>
</tr>
<tr>
<td>Normal (n=6)</td>
<td>2.50±0.44</td>
</tr>
<tr>
<td>Heart failure (n=6)</td>
<td>1.25±0.23*</td>
</tr>
</tbody>
</table>

The parameters for [3H]dihydro-FK506 binding and [3H]ryanodine binding to cardiac muscle SR fractions were determined by Scatchard analysis. The ratio of the $B_{max}$ values for [3H]dihydro-FK506 and [3H]ryanodine binding provides an estimate of the stoichiometry of FKBP per RyR. Data represent mean±SD.

* $P<0.05$ vs. control.
fluorescence was clearly localized in RyR in both normal and failing SR vesicles, no other bands being fluorescently labeled. Figure 4A shows typical examples of the changes in MCA fluorescence produced by the addition of FK506 under the same conditions as those used for the Ca$^{2+}$ leak assay. After Ca$^{2+}$ uptake, the addition of FK506 induced an increase in MCA fluorescence at a faster rate than that of the Ca$^{2+}$ leak in normal SR vesicles (compare Figure 4A with Figure 2A), whereas it produced only a slight increase in MCA fluorescence in failing SR vesicles. As shown in Figure 4B, in normal SR vesicles, the amplitude of the FK506-induced change in MCA fluorescence increased as the concentration of FK506 was increased. In failing SR vesicles, however, FK506 produced only a small effect on MCA fluorescence even at its highest concentrations.

Figure 2. A, Representative time courses of Ca$^{2+}$ uptake and ensuing Ca$^{2+}$ leak in SR vesicles isolated from normal and failing canine hearts. Change in extravesicular Ca$^{2+}$ concentration was measured with fluo 3, as described under Methods. B, Effect of various concentrations of FK506 on SR Ca$^{2+}$ leak in SR vesicles isolated from normal (C, n=6) and failing (●, n=6) canine hearts. Data represent mean±SD.

FK506 had no effect on the background fluorescence of unla-
beled SR vesicles in either normal or failing SR vesicles. Changes in MCA fluorescence did not occur during an ionomycin-induced Ca$^{2+}$ leak in either normal or failing SR vesicles (not shown), suggesting that the conformational change in RyR mediating the FK506-induced or spontaneous Ca$^{2+}$ leak is not under the control of changes in intravesicular [Ca$^{2+}$]. Furthermore, even when the extravesicular [Ca$^{2+}$] was strictly buffered to 0.3 μmol/L (with 5 mmol/L EGTA-calcium buffer) during the FK506-induced Ca$^{2+}$ leak, the change in MCA fluorescence was still observed (not shown), indicating that the FK506-induced conformational change in RyR is not under the control of changes in extravesicular [Ca$^{2+}$] either.

FKBP12.6 Expression in Normal and Failing SR Vesicles
As shown in Figure 5, an immunoreactive band for FKBP12.6 was detected in both normal and failing SR vesicles. However, the expression level of FKBP12.6 was significantly lower (0.80±0.43) in failing SR vesicles than in normal SR vesicles (2.34±0.37).

Discussion
The major findings of this study are as follows. First, the stoichiometry of FKBP per RyR was significantly decreased in failing SR vesicles. Second, FK506, which binds to the FKBP12.6 associated with the RyR, caused a dose-dependent Ca$^{2+}$ leak in normal SR vesicles that showed a close paral-
elism with the conformational change in RyR. Third, in failing SR vesicles, a prominent Ca$^{2+}$ leak was observed even in the absence of FK506, and FK506 produced little or no further increase in Ca$^{2+}$ leak and only a slight conformational change in RyR. Fourth, as we expected in view of the above results, the level of protein expression of FKBP12.6 was indeed significantly decreased in failing SR vesicles.

The most important new concept to emerge from these findings is that the abnormal Ca$^{2+}$ leak observed in failing SR vesicles is due to a decreased stoichiometry of FKBP/RyR and
the resultant conformational change in RyR, which leads to RyR instability. We interpret the time course of the FK506-induced change in MCA fluorescence as indicating that a conformational change in RyR occurred as a consequence of the dissociation of FKBP12.6 from RyR. Our results indicate that 50% of the FKBP12.6 molecules have already been lost from RyR in heart failure, whereas 4 FKBP12.6 molecules to be dissociated remain to be bound in the normal heart. Hence, treatment with FK506 would be expected to produce a much more conspicuous RyR conformational change in normal SR vesicles than in failing SR vesicles (in which a considerable portion of the RyR-bound FKBP12.6 has already been dissociated). Furthermore, the fact that the time course of the change in MCA fluorescence is much faster than that of the Ca2+ leak suggests that dissociation of the RyR-bound FKBP12.6 and the resultant RyR conformational change is a causative mechanism for the observed Ca2+ leak.

Our view, as deduced from the above findings, is schematically illustrated in Figure 6. When sufficiently high concentrations of FK506 (or rapamycin) are applied to cardiac myocytes, cooperation among the 4 RyR subunits is disrupted, thus destabilizing the channel and in turn inducing an abnormal Ca2+ leak. Presumably, equivalent phenomena are occurring in failing hearts even without the addition of FKBP-dissociating agents. This Ca2+ leak will decrease SR Ca2+ loading and elevate basal cytosolic Ca2+ levels during diastole, leading to contractile and relaxation dysfunction.

Before we can firmly advance this as an explanation, several questions remain to be resolved. Because FK506 binds to FKBP as well as to FKBP12.6, we need to examine the possibility that the Bmax of [3H]dihydro-FK506 binding may indicate mixed binding of FK506, that is, to both FKBP12.6 and FKBP12. In this regard, we should note that in cardiac muscle, the type of FKBP bound to RyR is solely FKBP12.6 and that FKBP12 exists as a soluble form in the cytoplasm. Moreover, Lam et al showed that only FKBP12.6 was

Figure 4. A, Representative time courses of change in MCA fluorescence in absence or presence of FK506 during Ca2+ leak in SR vesicles isolated from normal and failing canine hearts. MCA fluorescence signal (arbitrary value) was recorded under same conditions as those used for Ca2+ leak assays, except that solution used was devoid of fluo 3. B, Effect of FK506 on conformational change in RyR during Ca2+ leak in SR vesicles isolated from normal (○; n=6) and failing (●; n=6) canine hearts. Changes in fluorescence are expressed as (F−F0)/F0×100 (%), where F0 is before addition of FK506 and F after addition of FK506. Data represent mean±SD.

Figure 5. A, Protein expression of FKBP12.6 in SR vesicles isolated from normal and failing canine hearts. Lane 1, 20 ng of FKBP12.6; lane 2, 100 μg of normal SR; lane 3, 100 μg of failing SR. Bands corresponding to FKBP12.6 are indicated by arrow. Position of size markers (Bio-Rad) is indicated on left. For details of experiments and antibodies used, see Methods. B, Statistical comparison of extent of FKBP12.6 expression between normal (n=5) and failing (n=5) SR vesicles. FKBP12.6 expression was lower in failing SR vesicles than in normal SR vesicles. Data represent mean±SD.

Figure 6. Altered interaction of FKBP12.6 with RyR in heart failure. Abnormal Ca2+ leak through the RyR is present in heart failure, presumably caused by partial loss of RyR-bound FKBP12.6 and resultant conformational change in RyR. This leak may cause Ca2+ overload and consequent diastolic dysfunction, as well as systolic dysfunction.
clearly detected (with no FKBP12) in a cardiac SR vesicle preparation that was similar to our preparation (see their Figure 5). In addition, in our study, the binding isotherm of [3H]dihydro-FK506 to cardiac SR vesicles is a simple hyperbola (yielding a straight line in a Scatchard analysis), a curve that is indicative of a single class of FK506 binding site. Taken together, the above evidence relating to [3H]dihydro-FK506 binding in cardiac SR vesicles indicates specific [3H]dihydro-FK506 binding to RyR-associated FKBP12.6.

The presumed stoichiometry of 4 mol FKBP12.6 per RyR tetramer relies on the assumption that the RyR is the predominant or only SR protein that binds FKBP12.6. In fact, Timmerman et al have already confirmed that this is the case on the basis of the following findings. After the endogenous FKBP of cardiac SR was exchanged for GST-FKBP12.6 fusion protein, SR samples were solubilized with CHAPS and affinity-purified on a GST-Sepharose affinity column. The cardiac RyR (RyR-2) was the predominant protein that was tightly bound to the GST-FKBP12.6 in these SRs.

It might be questioned why the concentration of FK506 required to induce a Ca\(^{2+}\) leak and protein conformational change in RyR was considerably higher than that needed for FK506-FKBP12.6 binding. Ahern et al showed that the concentration of FK506 required for an increase in the open probability of RyR is 3 to 20 \(\mu\)mol/L, and Timmerman et al \(^{17}\) demonstrated that the \(EC_{50}\) for dissociation of FKBP from RyR was as high as 0.12 to 0.5 \(\mu\)mol/L. The concentration of FK506 required for its binding to FKBP12.6 may be higher under physiological conditions than in the solubilized conditions used for [3H]dihydro-FK506 binding assays.

Shou et al \(^{19}\) used embryonic stem cells to generate mutant mice deficient in FKBP12 and demonstrated that although these FKBP12- (not 12.6)-deficient mice had normal skeletal muscle, they had severe dilated cardiomyopathy. Although FKBP12.6 seems to play an important role in the modulation of ryanodine receptor function in SR vesicles, more work is clearly needed before we can fully understand the roles of FKBP12 and 12.6 in cardiac function in the intact heart.

Finally, it remains to be elucidated why FKBP12.6 is partially lost in heart failure. Very recently, Marx et al \(^{24}\) demonstrated that hyperphosphorylation of RyR mediated by protein kinase A causes dissociation of FKBP12.6 from RyR, resulting in defective channel function due to increased sensitivity to Ca\(^{2+}\)-induced activation. Conceivably, this mechanism might be involved in the partial loss of FKBP12.6 seen in heart failure.

In conclusion, a prominent Ca\(^{2+}\) leak through the RyR was observed in a canine model of heart failure, and this is presumably caused by a partial loss of RyR-bound FKBP12.6. This abnormal Ca\(^{2+}\) leak could lead to systolic and diastolic dysfunction even in the absence of a change in SR Ca\(^{2+}\)-ATPase activity. This new concept concerning the mechanism of cardiac dysfunction could inform the development of a new type of drug (ie, a Ca\(^{2+}\) channel stabilizer) for the treatment of patients with heart failure.

Acknowledgments

This work was supported by a grant-in-aid for scientific research from the Ministry of Education in Japan (grant C 11670684) and by a Health Sciences Research Grant for Comprehensive Research on Aging and Health from the Ministry of Health and Welfare, Japan. We thank Dr Noriaki Ikemoto (Department of Muscle Research, Boston Biomedical Research Institute, Boston, Mass) for a critical reading of the manuscript and helpful suggestions.

References

1. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol. 1983;245:C1–C14.
Altered Stoichiometry of FKBP12.6 Versus Ryanodine Receptor as a Cause of Abnormal Ca\(^{2+}\) Leak Through Ryanodine Receptor in Heart Failure

Masafumi Yano, Kaoru Ono, Tomoko Ohkusa, Masae Suetsugu, Masateru Kohno, Takayuki Hisaoka, Shigeki Kobayashi, Yuji Hisamatsu, Takeshi Yamamoto, Michihiro Kohno, Naoya Noguchi, Shin Takasawa, Hiroshi Okamoto and Masunori Matsuzaki

_Circulation_. 2000;102:2131-2136
doi: 10.1161/01.CIR.102.17.2131

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2000 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circ.ahajournals.org/content/102/17/2131